Literature DB >> 16945043

Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents.

L Lee Dupuis1, Anna Taddio, Elizabeth N Kerr, Andrea Kelly, Linda MacKeigan.   

Abstract

STUDY
OBJECTIVE: To develop and validate an instrument to assess nausea intensity in children aged 4-18 years.
DESIGN: Prospective, descriptive study.
SETTING: Tertiary-quaternary, university-affiliated pediatric hospital. PATIENTS: Four pediatric inpatient groups (177 patients): group 1 (107), those receiving cancer chemotherapy; group 2 (24), those receiving cancer chemotherapy before hematopoietic stem cell transplantation; group 3 (23), those with cancer who were not receiving cancer chemotherapy; and group 4 (23), those without cancer. INTERVENTION: We developed a scale with a standard script for administration, the Pediatric Nausea Assessment Tool (PeNAT). Revisions were made after face validity testing with clinicians and parents, and pilot testing with 15 inpatients undergoing chemotherapy.
MEASUREMENTS AND MAIN RESULTS: The PeNAT scores were obtained 4-24 hours after chemotherapy in groups 1 and 2. Dietary intake scores and number of emetic episodes were recorded for the 4 hours before PeNAT administration for all patients in group 2 and 36 patients in group 1. Parents of a subset of patients made an independent assessment of their child's nausea and pain intensities immediately before PeNAT administration. Reliability was evaluated in groups 1 and 2 by correlating the first and second (obtained 1 hr after the first) PeNAT scores. Construct validity was evaluated by comparing PeNAT scores in groups 1-4. Criterion-related validity was evaluated by correlating PeNAT scores with emetic episodes and dietary intake. Convergent and discriminant validity were evaluated by correlating PeNAT scores with parental assessments of nausea and pain. Significant differences in PeNAT scores were noted among the study groups (p=0.035). Moderate correlation was noted between the first and second PeNAT scores (Spearman rho = 0.649). The PeNAT scores correlated modestly with emetic episodes (Spearman rho = 0.322) but not with dietary intake (Spearman rho = -0.217). Children's PeNAT scores correlated moderately with their parents' assessment of nausea (Spearman rho = 0.442), whereas little correlation was seen between children's PeNAT scores and parents' assessment of pain (Spearman rho = 0.167).
CONCLUSION: The PeNAT is a new instrument that can be used by children to assess nausea intensity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16945043     DOI: 10.1592/phco.26.9.1221

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  36 in total

Review 1.  Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database.

Authors:  Puja Khanna; Nikhil Agarwal; Dinesh Khanna; Ron D Hays; Lin Chang; Roger Bolus; Gil Melmed; Cynthia B Whitman; Robert M Kaplan; Rikke Ogawa; Bradley Snyder; Brennan Mr Spiegel
Journal:  Am J Gastroenterol       Date:  2013-12-17       Impact factor: 10.864

2.  Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.

Authors:  Molly McFatrich; Jennifer Brondon; Nicole R Lucas; Pamela S Hinds; Scott H Maurer; Jennifer W Mack; David R Freyer; Shana S Jacobs; Justin N Baker; Catriona Mowbray; Mian Wang; Sharon M Castellino; Allison Barz Leahy; Bryce B Reeve
Journal:  Cancer       Date:  2019-09-25       Impact factor: 6.860

3.  Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study.

Authors:  Priya Patel; Sara R Lavoratore; Jacqueline Flank; Meaghan Kemp; Ashlee Vennettilli; Helen Vol; Tracey Taylor; Elyse Zelunka; Anne Marie Maloney; Paul C Nathan; L Lee Dupuis
Journal:  Support Care Cancer       Date:  2019-06-08       Impact factor: 3.603

Review 4.  Self-report of symptoms in children with cancer younger than 8 years of age: a systematic review.

Authors:  D Tomlinson; L Tigelaar; S Hyslop; T Lazor; L L Dupuis; K Griener; J Oliveria; L Sung
Journal:  Support Care Cancer       Date:  2017-05-12       Impact factor: 3.603

5.  Treatment of Chemotherapy-Induced Nausea in Cancer Patients.

Authors:  Julie L Ryan
Journal:  Eur Oncol       Date:  2010

Review 6.  Child and adolescent self-report symptom measurement in pediatric oncology research: a systematic literature review.

Authors:  Laura C Pinheiro; Molly McFatrich; Nicole Lucas; Jennifer S Walker; Janice S Withycombe; Pamela S Hinds; Lillian Sung; Deborah Tomlinson; David R Freyer; Jennifer W Mack; Justin N Baker; Bryce B Reeve
Journal:  Qual Life Res       Date:  2017-09-06       Impact factor: 4.147

7.  Staff Perceptions of Symptoms, Approaches to Assessment, and Challenges to Assessment Among Children With Cancer.

Authors:  Lauri A Linder; Sarah E Wawrzynski
Journal:  J Pediatr Oncol Nurs       Date:  2018-04-13       Impact factor: 1.636

8.  2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.

Authors:  L Lee Dupuis; Lillian Sung; Alexander Molassiotis; Andrea D Orsey; Wim Tissing; Marianne van de Wetering
Journal:  Support Care Cancer       Date:  2016-08-26       Impact factor: 3.603

9.  Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study.

Authors:  J Flank; T Schechter; P Gibson; D L Johnston; A D Orsey; C Portwine; L Sung; L L Dupuis
Journal:  Support Care Cancer       Date:  2017-08-30       Impact factor: 3.603

10.  Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate.

Authors:  Helen Vol; Jacqueline Flank; Sara R Lavoratore; Paul C Nathan; Tracey Taylor; Elyse Zelunka; Anne Marie Maloney; L Lee Dupuis
Journal:  Support Care Cancer       Date:  2015-09-03       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.